Turner syndrome screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 4: Line 4:
==Overview==
==Overview==


There is insufficient evidence to recommend routine screening for [disease/malignancy].  
Screening for complications of [[Turner syndrome]] starts as early as a [[prenatal]] visit. Abnormal maternal [[serum]] screening tests or an [[ultrasound]] detecting [[structural anomalies]] such [[shortened limbs]], [[cystic hygromas]], [[congenital heart defects]] or increased [[swelling]] of the hands or feet may point towards a diagnosis of [[Turner syndrome]]. As the years progress, screening involves a multidisciplinary combination of lab investigations (such as [[serum]] [[gonadotrophins]], [[liver function tests]], [[renal function tests]], etc), referral to other departments ([[cardiology]], [[endocrinology]], [[ophthalmology]], etc) and tools such as [[DEXA scans]], [[X-rays]], [[echocardiography]], etc.  
 
OR
 
According to the [guideline name], screening for [disease name] is not recommended.
 
OR
 
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].


==Screening==
==Screening==


*The ‘Diagnostic study of choice’ page in this microchapter helps to integrate the below screening modalities in a clinical setting.  
*The ‘Diagnostic study of choice’ page in this microchapter helps to integrate the below screening modalities in a clinical setting.  
*In addition, frequent referral to departments such as cardiology, nephrology, embryology, genetics, endocrinology, otorhinolaryngology, ophthalmology, dermatology and rheumatology ensures that a detail physical examination can be done to catch early signs of associated conditions seen in Turner syndrome.  
*In addition, frequent referral to departments such as [[cardiology]], [[nephrology]], [[embryology]], [[genetics]], [[endocrinology]], [[otorhinolaryngology]], [[ophthalmology]], [[dermatology]] and [[rheumatology]] ensures that a detail physical examination can be done to catch early signs of associated conditions seen in [[Turner syndrome]].  
*Screening newborns usually first involves a bed side ultrasonography which may reveal nuchal translucency, structural abnormalities such as shortened limbs, lymphedema of hands and feed, cystic hygroma and cardiac defects.  
*Screening newborns usually first involves a bed side [[ultrasonography]] which may reveal [[nuchal translucency]], [[structural abnormalities]] such as [[shortened limbs]], [[lymphedema]] of hands and feed, [[cystic hygroma]] and [[cardiac defects]].  
*This is used along with a maternal serum screening test which detects high inhibin B, low unconjugated estriol, high human chorionic gonadotrophin and low alpha feto protein.  
*This is used along with a maternal [[serum]] screening test which detects high [[inhibin B]], low [[unconjugated estriol]], high [[human chorionic gonadotrophin]] and low [[alpha feto protein]].  
*Once a diagnosis has been established, screening is aimed at detecting complications.  
*Once a diagnosis has been established, screening is aimed at detecting complications.  
*Individuals on growth hormone should be screened regularly with forward bend tests and X-rays as the therapy exposes underlying scoliosis.  
*Individuals on [[growth hormone]] should be screened regularly with forward bend tests and [[X-rays]] as the therapy exposes underlying [[scoliosis]].  
*Echocardiography for cardiac structural abnormalities especially aortic dilation that predisposes the individual to aortic dissection and sudden cardiac death.  
*[[echocardiography]] for [[cardiac structural abnormalities]] especially [[aortic dilation]] that predisposes the individual to [[aortic dissection]] and sudden [[cardiac death]].  
**The aortic severity index is a useful prognostic indicator when assessing for the risk of aortic dilatation. <ref name="pmid29344338">{{cite journal| author=Shankar RK, Backeljauw PF| title=Current best practice in the management of Turner syndrome. | journal=Ther Adv Endocrinol Metab | year= 2018 | volume= 9 | issue= 1 | pages= 33-40 | pmid=29344338 | doi=10.1177/2042018817746291 | pmc=5761955 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29344338  }} </ref>
**The [[aortic severity index]] is a useful [[prognostic]] indicator when assessing for the risk of [[aortic dilatation]]. <ref name="pmid29344338">{{cite journal| author=Shankar RK, Backeljauw PF| title=Current best practice in the management of [[Turner syndrome]]. | journal=Ther Adv Endocrinol Metab | year= 2018 | volume= 9 | issue= 1 | pages= 33-40 | pmid=29344338 | doi=10.1177/2042018817746291 | pmc=5761955 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29344338  }} </ref>
**It is the aortic diameter corrected for body surface area and a score of more than 2.3 cm per metre square indicates a high risk of aortic dissection (2-2.3 cm per metre square is considered as moderate risk).  
**It is the [[aortic]] diameter corrected for body surface area and a score of more than 2.3 cm per metre square indicates a high risk of [[aortic dissection]] (2-2.3 cm per metre square is considered as moderate risk).  
**The advice offered to moderate risk patients is restriction of activities and that offered to high risk patients is that they should completely avoid competitive sports and intensive weight training.  
**The advice offered to moderate risk patients is restriction of activities and that offered to high risk patients is that they should completely avoid competitive sports and intensive weight training.  
*Renal ultrasound for structural abnormalities like duplication of the collecting system and horseshoe shaped kidney.
*[[Renal]] [[ultrasound]] for structural abnormalities like duplication of the collecting system and [[horseshoe shaped kidney]].
*Dual energy x-ray absorptiometry (DEXA) scans may be done to test bone mineral density.  
*Dual energy x-ray absorptiometry (DEXA) scans may be done to test [[bone mineral density]].  
*Audiology for sensorineural and conductive hearing loss.
*[[Audiology]] for [[sensorineural]] and conductive hearing loss.
*Multidisciplinary neuropsychiatric evaluation should be done at major transitional stages such preschool entry and high school entry. <ref name="pmid12612263">{{cite journal| author=Frías JL, Davenport ML, Committee on Genetics and Section on Endocrinology| title=Health supervision for children with Turner syndrome. | journal=Pediatrics | year= 2003 | volume= 111 | issue= 3 | pages= 692-702 | pmid=12612263 | doi=10.1542/peds.111.3.692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12612263  }} </ref>
*Multidisciplinary [[neuropsychiatric]] evaluation should be done at major transitional stages such preschool entry and high school entry. <ref name="pmid12612263">{{cite journal| author=Frías JL, Davenport ML, Committee on [[genetics]] and Section on [[endocrinology]]| title=Health supervision for children with Turner syndrome. | journal=Pediatrics | year= 2003 | volume= 111 | issue= 3 | pages= 692-702 | pmid=12612263 | doi=10.1542/peds.111.3.692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12612263  }} </ref>
*ECGs should be performed as long QT syndrome frequently occurs secondary to medication used to treat complications of Turner syndrome.
*[[ECGs]] should be performed as [[long QT syndrome]] frequently occurs secondary to medication used to treat complications of [[Turner syndrome]].
*Individuals with a Y karyotypic abnormality should be screened with fluorescent insitu hybridization and polymerase chain reaction techniques, to detect the risk of developing a gonadoblastoma.  
*Individuals with a Y [[karyotypic]] abnormality should be screened with [[fluorescent insitu hybridization]] and [[polymerase chain reaction]] techniques, to detect the risk of developing a [[gonadoblastoma]].  


*Laboratory investigations that may help in screening include:  <ref name="pmid20081420">{{cite journal| author=Wolff DJ, Van Dyke DL, Powell CM, Working Group of the ACMG Laboratory Quality Assurance Committee| title=Laboratory guideline for Turner syndrome. | journal=Genet Med | year= 2010 | volume= 12 | issue= 1 | pages= 52-5 | pmid=20081420 | doi=10.1097/GIM.0b013e3181c684b2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20081420  }} </ref>
*Laboratory investigations that may help in screening include:  <ref name="pmid20081420">{{cite journal| author=Wolff DJ, Van Dyke DL, Powell CM, Working Group of the ACMG Laboratory Quality Assurance Committee| title=Laboratory guideline for Turner syndrome. | journal=Genet Med | year= 2010 | volume= 12 | issue= 1 | pages= 52-5 | pmid=20081420 | doi=10.1097/GIM.0b013e3181c684b2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20081420  }} </ref>
*#Serum gonadotrophins and anti Mullerian hormone- ovarian reserve.  
*#[[serum]] [[gonadotrophins]] and [[anti Mullerian hormone]]- ovarian reserve.  
*#Renal function tests – renal failure secondary to structural abnormalities.
*#[[renal function tests]] [[renal failure]] secondary to structural abnormalities.
*#Thyroid function tests – thyroiditis, hypothyroidism, hyperthyroidism
*#[[Thyroid function tests]] [[thyroiditis]], [[hypothyroidism]], [[hyperthyroidism]]
*#Liver function tests – focal nodular hyperplasia
*#[[liver function tests]] [[focal nodular hyperplasia]]
*#Serum IgA, IgA anti endomysium antibodies and IgA antigliadin antibodies – Celiac disease
*#[[serum]] IgA, [[IgA anti endomysium antibodies]] and [[IgA antigliadin antibodies]] [[Celiac disease]]
*#Lipid profile – hyperlipidemia
*#Lipid profile – [[hyperlipidemia]]
*#Oral glucose tolerance test and serum glycosylated hemoglobin – for type 2 diabetes mellitus.  
*#Oral glucose tolerance test and [[serum]] [[glycosylated hemoglobin]] – for type 2 [[diabetes mellitus]].  
*#Serum 25-hydroxyvitamin D- Vitamin D deficiency.
*#[[serum]] 25-hydroxyvitamin D- [[Vitamin D deficiency]].
 
 
 
== 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines<ref name="pmid30121240">{{cite journal| author=Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM | display-authors=etal| title=2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=J Am Coll Cardiol | year= 2019 | volume= 73 | issue= 12 | pages= 1494-1563 | pmid=30121240 | doi=10.1016/j.jacc.2018.08.1028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30121240  }}</ref> ==


=== Diagnostic and Therapeutic Recommendations for Turner Syndrome ===
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen" |'''1.'''Women with Turner syndrome should be evaluated for bicuspid aortic valve, coarctation of the aorta, and enlargement of the ascending aorta. ''(Level of Evidence: B-NR)''
|}
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon" |'''1.'''Prophylactic replacement of the aortic root or ascending aorta in adults with Turner syndrome is reasonable when the aortic diameter is 2.5 cm/m2 or greater.
''(Level of Evidence: B-NR)''
|}
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
Line 51: Line 61:


[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:Syndromes]]
[[Category:Syndromes]]

Latest revision as of 18:56, 15 December 2022

Turner syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Turner syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Turner syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Turner syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Turner syndrome screening

CDC on Turner syndrome screening

Turner syndrome screening in the news

Blogs on Turner syndrome screening

Directions to Hospitals Treating Turner syndrome

Risk calculators and risk factors for Turner syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akash Daswaney, M.B.B.S[2]

Overview

Screening for complications of Turner syndrome starts as early as a prenatal visit. Abnormal maternal serum screening tests or an ultrasound detecting structural anomalies such shortened limbs, cystic hygromas, congenital heart defects or increased swelling of the hands or feet may point towards a diagnosis of Turner syndrome. As the years progress, screening involves a multidisciplinary combination of lab investigations (such as serum gonadotrophins, liver function tests, renal function tests, etc), referral to other departments (cardiology, endocrinology, ophthalmology, etc) and tools such as DEXA scans, X-rays, echocardiography, etc.

Screening


2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[4]

Diagnostic and Therapeutic Recommendations for Turner Syndrome

Class I
1.Women with Turner syndrome should be evaluated for bicuspid aortic valve, coarctation of the aorta, and enlargement of the ascending aorta. (Level of Evidence: B-NR)
Class IIa
1.Prophylactic replacement of the aortic root or ascending aorta in adults with Turner syndrome is reasonable when the aortic diameter is 2.5 cm/m2 or greater.

(Level of Evidence: B-NR)

References

  1. Shankar RK, Backeljauw PF (2018). "Current best practice in the management of [[Turner syndrome]]". Ther Adv Endocrinol Metab. 9 (1): 33–40. doi:10.1177/2042018817746291. PMC 5761955. PMID 29344338. URL–wikilink conflict (help)
  2. Frías JL, Davenport ML, Committee on genetics and Section on endocrinology (2003). "Health supervision for children with Turner syndrome". Pediatrics. 111 (3): 692–702. doi:10.1542/peds.111.3.692. PMID 12612263.
  3. Wolff DJ, Van Dyke DL, Powell CM, Working Group of the ACMG Laboratory Quality Assurance Committee (2010). "Laboratory guideline for Turner syndrome". Genet Med. 12 (1): 52–5. doi:10.1097/GIM.0b013e3181c684b2. PMID 20081420.
  4. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM; et al. (2019). "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". J Am Coll Cardiol. 73 (12): 1494–1563. doi:10.1016/j.jacc.2018.08.1028. PMID 30121240.

Template:WH Template:WS